DUBLIN, Jan 25, 2017 /PRNewswire/ --
Research and Markets has announced the addition of the "Global Pharmerging Markets 2017-2021" report to their offering.
The global pharmerging market to grow at a CAGR of 12.88% during the period 2017-2021.
Global Pharmerging Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Although the adoption of targeted therapies in emerging markets is low, it is expected to increase substantially during the forecast period, particularly in the long term. With the growing incidence of chronic diseases such as cancer, which requires specific therapies for the effective treatment, the adoption of targeted therapies is expected to witness substantial upward momentum. For instance, in India, the prevalence of cancer is expected to increase by 25%-40% in the next 10 years.
The increasing awareness among physicians about the advantages of targeted therapies will certainly lead to an increase in adoption rates. Research studies done across the geographies have demonstrated that targeted therapy has increased the survival rate and the cure rate in cancer patients. These drugs are expected to work effectively in the treatment of various cancers such as lung cancer, breast cancer, chronic myeloid leukemia and lymphomas. Although, the cost of these targeted therapies is higher than the traditional ones, the growing awareness toward government subsidies and reimbursements could improve the adoption of such therapies even in the pharmerging nations.
According to the report, the pharmaceutical market in developed economies has reached its maturity phase and hence, is witnessing stagnance in terms of growth. This is primarily due the unfavorable economic conditions and patent expiries of innovator products. In order to maintain a healthy growth trajectory, the companies started exploring for new sources of revenue. In addition, the healthcare budget cuts in developed markets such as the US, has further driven the vendors' focus toward emerging economies.
Other prominent vendors
- Abbott Laboratories
- Alexion Pharmaceuticals
- Astellas Pharma
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Eli Lilly
- Takeda Pharma
- Teva Pharmaceutical Industries
- Valeant Pharmaceuticals
Key Topics Covered:
Part 01: Executive summary
Part 02: Scope of the report
Part 03: Market research methodology
Part 04: Introduction
Part 05: Global pharmaceutical market
Part 06: Road to pharmerging markets
Part 07: Pharmerging markets
Part 08: Market landscape
Part 09: Market segmentation by geography
Part 10: Market overview of tier I countries
Part 11: Market overview of tier II countries
Part 12: Market overview of tier III countries
Part 13: Market drivers
Part 14: Impact of drivers
Part 15: Market challenges
Part 16: Impact of drivers and challenges
Part 17: Market trends
Part 18: Vendor landscape
Part 19: Key vendor analysis
Part 20: Appendix
For more information about this report visit http://www.researchandmarkets.com/research/8qql9z/global
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-pharmerging-markets-grow-of-1288-2017-2021-with-astrazeneca-glaxosmithkline-pfizer--sanofi-novartis-leading-the-way---research-and-markets-300396527.html
SOURCE Research and Markets